We have discovered a vast, expanded universe of novel proteins encoded by the human genome. In analyzing these proteins, we elucidate their respective biological functions, refining our understanding of the molecular underpinnings of human biology and disease. Armed with this knowledge, we’re aiming to create breakthrough medicines for a multitude of diseases.

Case 45 is building the most advanced precision AI model for oncology, rooted in cancer evolutionary biology. They are targeting healthcare (oncology prognostic and predictive tests in unmet need), and pharma (drug development) business models.

March Biosciences is developing advanced cell therapies, targeting complex diseases like cancer and genetic disorders through precision medicine approaches. Their lead asset, MB-105, selectively targets CD5, a widely expressed antigen both in normal and malignant T-cells.

Latus Bio is developing curative medicines for neurological diseases, enabled by unprecedented AAV capsids that unlock new possibilities for patient care.

Rubedo discovers and develops medicines to keep you biologically young by targeting the pathologic cells that drive aging.

Developing the next generation of induced-proximity medicines